Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment

ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) gene fusion is an important driver mutation and therapeutic target and identified in 1–2% of NSCLC [ [1] Huang L. Jiang S. Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J. Hematol. Oncol. 2020; 13: 143 Crossref PubMed Scopus (24) Google Scholar ]. Although ROS1 fusion has a relatively low incidence of NSCLC, the result from clinical trial has demonstrated excellent efficacy of crizotinib [ [2] Shaw A.T. Ou S.H. Bang Y.J. et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014; 371: 1963-1971 Crossref PubMed Scopus (1183) Google Scholar ]. In present, ROS1 has multiple